Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Gets Taiwan FDA Approval for Liquid Handling Platform

NEW YORK (GenomeWeb) – Vela Diagnostics said on Friday that the Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.

The Sentosa SX101 is a multi-purpose liquid handling platform that can process 21 separate sample types. It features open channel capabilities for automated sample extraction, PCR setup, next-generation sequencing library preparation, and Sanger sequencing cleanup. The platform is validated for use with Vela's automated and integrated PCR and NGS workflow.

With the approval, Vela Diagnostics said it plans to enter the IVD market and expand its approved portfolio in Taiwan.

In November, Singapore-based Vela said that its Sentosa SX Cell-Free DNA Kit for use on the SX101 platform garnered CE marking for IVD use.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.